Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.

Most drugs withdrawn from the market because of serious toxicities never make it back. But Biogen Idec succeeded in getting its multiple sclerosis (MS) drug Tysabri reintroduced in less than 16 months ...

MND patients in the UK denied access to lifesaving drug tofersen, despite Biogen supplying it free, due to NHS covering ...

The Prognostic Lung Fibrosis Consortium (PROLIFIC), a collaborative consortium advancing biomarker tools for pulmonary fibrosis (PF) research, announced today that the PROLIFIC Risk Score has been ...

Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and ...

-- First Patient Expected to be Dosed Next Week with Intranasal Foralumab -- PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi (R) (Lecanemab) Anti-Amyloid ...

From crushing grapes in Napa Valley to crunching numbers on the U.S.’s largest privately funded Randomized Controlled Trial (RCT) ever, Patrick Krause - now Data Director at Open Research - has built ...

Professor Hobbs’ research currently centers around index insurance—a promising approach to protecting farmers from weather-related losses. Unlike traditional insurance that requires individual claim ...

Background Clinical trials established the efficacy and safety of natalizumab. Data are needed over longer periods of time and in the clinical practice setting. Objective To evaluate long-term safety ...

View post: This Widebody Rolls-Royce Dawn Completely Ditches the Iconic Grille The motorsport program focuses on endurance racing. Next year Genesis Magma Racing enters the WEC series with its own ...

Genesis Magma Racing's first GMR-001 Hypercar test chassis is almost ready to hit the track, following the installation and fire-up of its twin-turbo V8 earlier this month in the south of France. Work ...